Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
Referrals to patient-related programs or resources
Donations, website, or event-related assistance
For medical questions, we encourage you to review our information with your doctor.
For epidemic (AIDS-associated) and iatrogenic (transplant related) Kaposi sarcoma (KS), it is most important to treat any immune deficiency that exists, as well as any related infections.
For people with HIV or AIDS, this means using combinations of anti-HIV drugs. This is known as highly active antiretroviral therapy (HAART). For many AIDS patients, HAART may be the only treatment needed to shrink the KS lesions and to keep them under control.
In organ-transplant patients whose immune systems are suppressed by drugs, stopping, lowering or changing the drugs may be helpful. Sirolimus and everolimus are new drugs that may control the KS lesions as well as prevent organ rejection.
New KS lesions are more likely to develop when a patient’s blood test results for Kaposi sarcoma herpesvirus (KSHV) are positive. The risk of developing new lesions is lower when antiviral medicines such as ganciclovir or foscarnet are used. These medicines may help prevent new lesions but they do not help existing lesions get better. They can also cause serious side effects.
KS lesions tend to get worse if you develop bacterial or other active infections. Therefore, it is very important to do what you can to lower your risk of bacterial infections and to treat active infections promptly if they do occur.
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Bhutani M et al. Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. Semin Oncol. 2015; 42(2):223-246.
Curtiss P, Strazzulla LC, Friedman-Kien AE. An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment. Dermatology and Therapy. 2016;6(4):465-470.
Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults. Geneva: World Health Organization; 2014. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305417/
National Cancer Institute Physician Data Query (PDQ): Kaposi sarcoma treatment - Health Professional Version. 01/30/2018. Accessed at https://www.cancer.gov/types/soft-tissue-sarcoma/hp/kaposi-treatment-pdq accessed on March 12, 2018.
Tian R, Liao Q, and Chen X. Prevention and Treatment of KSHV-associated Diseases with Antiviral Drugs. Virologica Sinica. 2008; 23 (6):486-495.
Last Revised: April 19, 2018
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Our lifesaving work is made possible thanks to generous supporters like you.
Donate now so we can continue to provide access to critical cancer information, resources, and support to improve lives of people with cancer and their families.